TheiaLife Sciences
- Biotech or pharma, therapeutic R&D
Theialife is advancing the world’s first oral therapy for pediatric myopia, with a Phase 3–ready candidate (ND10 ER) and seven novel preclinical ophthalmology assets. Spun out of Bioplus Life Sciences, our virtual platform combines global clinical experience with cutting-edge innovation. Backed by 15+ years of real-world data and regulatory support from Denmark’s Ministry of Health, we are preparing an IND filing for U.S. trials in 2025. With over 1,200 children safely treated to date, we offer a de-risked, first-in-class opportunity in a massive, underserved market. We are raising an $80M Series A/B round to advance our lead program through global Phase 3 trials and build a category-defining ophthalmology pipeline.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}